DOSING & ADMINISTRATION

NEMLUVIO offers Q4W dosing from the start1

LESS FREQUENT DOSING COMPARED TO THE OTHER BIOLOGIC FOR PN1,2

Image
NEMLUVIO® is administered 13 times a year compared with the other biologic at 26 times a year.
Image
NEMLUVIO® is administered 13 times a year compared with the other biologic at 26 times a year.

RECOMMENDED DOSING FOR PATIENTS 18 AND OLDER1

Patient WeightInitial DoseMaintenance Dose (Q4W)
Less than 198 lbs (90 kg)2 injections1 injection
Greater than or 
equal to 198 lbs (90 kg)
2 injections2 injections
Patient WeightInitial Dose
Less than 198 lbs (90 kg)2 injections
Greater than or 
equal to 198 lbs (90 kg)
2 injections
Patient WeightMaintenance
Dose (Q4W)
Less than 198 lbs (90 kg)1 injection
Greater than or 
equal to 198 lbs (90 kg)
2 injections

Each injection is 30 mg of NEMLUVIO

Administer NEMLUVIO seamlessly and safely

Watch the NEMLUVIO Demo Kit Video to see how to successfully administer NEMLUVIO to your patients

 

Visit the NEMLUVIO Patient Site to watch an injection training video for self-administering patients

NEMLUVIO® single dose, prefilled, dual chamber pen.

NEMLUVIO is uniquely designed for patient satisfaction1

  • Convenience of a prefilled self‑injectable pen1
  • >75% lower volume than the other biologic for PN (0.49 mL vs 2 mL)1,2
  • Room-temperature storage for up to 90 days within the labeled expiration period1

What patients should know before getting started

Keep the NEMLUVIO pen and all medicines out of the reach of children3  
  • It is best to store the NEMLUVIO pen in the refrigerator between 36 °F and 46 °F (2 °C to 8 °C)3
    • However, the NEMLUVIO pen can be stored at room temperature up to 77 °F (25 °C) for a single period up to 90 days3
    • Take the NEMLUVIO pen out of the refrigerator and let it come to room temperature for 30 to 45 minutes before continuing3
  • NEMLUVIO contains medicine (30 mg of lyophilized powder) in one chamber and water for dissolving the medicine in the other chamber
    • Before it can be injected, the lyophilized powder must be mixed with the water for dissolving the medicine3
    • After the medicine has dissolved, it must be used within 4 hours. If you have not used it within 4 hours, dispose of it3
  • Patients should mark their calendar ahead of time to remember when to take NEMLUVIO
  • The NEMLUVIO pen should not be used if it has been dropped on a hard surface or is damaged, cracked or broken3
  • The used NEMLUVIO pen should be disposed of right away after use in a sharps disposal container3
  • Patients should be encouraged to complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to NEMLUVIO treatment initiation1
Image
Instructions for Use PDF.

Instructions for Use

The NEMLUVIO Instructions for Use should be read carefully before using NEMLUVIO

Administration Overview

  • After dissolving, proceed right away with the injection to avoid any contamination or breakdown of medicine (degradation)3
    • Be careful not to shake the prefilled pen3
  • Select the injection site using the following chart3
    • Inject the pen in the abdomen (2 inches away from the navel), upper thigh, or the outer upper arm
    • Use a different injection site at least one inch away from the first injection site3 
Image
NEMLUVIO® may be administered via self injection or by a caregiver in the abdomen and thighs. NEMLUVIO® may be administered by a caregiver only in the outer upper arms.
Image
NEMLUVIO® may be administered via self injection or by a caregiver in the abdomen and thighs. NEMLUVIO® may be administered by a caregiver only in the outer upper arms.
Image
Galderma Patient Services for NEMLUVIO logo

Galderma Patient Services for NEMLUVIO

Helps patients start and stay on treatment by helping to navigate coverage and providing access to assistance programs and adherence support

Image

Patient and Practice Resources

Tools to help patients start and stay on treatment

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular.

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Please see full Prescribing Information, including Patient Information.